Abstract
Summary
The Asia-Pacific sarcopenia treatment market is expected to reach USD 861,882.42 thousand by 2030 from USD 547,450.80 thousand in 2022, growing at a CAGR of 5.9% in the forecast period of 2023 to 2030
Market Segmentation
Asia-Pacific Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, And Rest Of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Sarcopenia Treatment Market Dynamics
Driver
• Rising prevalence of sarcopenia
Restrain
• Lack of standardized diagnosis
Opportunity
• Strategic initiatives by key market players
Market Players
Some of the key market players operating in the Asia-Pacific sarcopenia treatment market are listed below:
• Abbott
• Nestlé Health Science (A subsidiary of Nestlé S.A.)
• Novartis AG
• Sanofi
• Haleon Group of Companies
• BASF SE
• DSM
• Fermenta Biotech Limited
• AstaReal Co., Ltd.
• Metagenics
• Wellona Pharma
• The Vitamin Company India
• Healing Pharma India Pvt. Ltd
• Others
Table of Contents
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF THE ASIA - PACIFIC SARCOPENIA TREATMENT MARKET 30
1.4 CURRENCY AND PRICING 32
1.5 LIMITATIONS 32
1.6 MARKETS COVERED 32
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 DBMR TRIPOD DATA VALIDATION MODEL 38
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.6 MULTIVARIATE MODELLING 42
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 42
2.8 MARKET END USER COVERAGE GRID 43
2.9 DBMR MARKET POSITION GRID 44
2.10 VENDOR SHARE ANALYSIS 46
2.11 SECONDARY SOURCES 47
2.12 ASSUMPTIONS 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 51
4.1 PESTEL ANALYSIS 52
4.2 PORTER’S FIVE FORCES MODEL 53
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 54
5 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: REGULATIONS 55
5.1 REGULATIONS IN U.S 55
5.2 REGULATIONS IN EUROPE 55
5.3 REGULATIONS IN AUSTRALIA 56
5.4 REGULATIONS IN SOUTH AFRICA 56
6 MARKET OVERVIEW 57
6.1 DRIVERS 59
6.1.1 RISING PREVALENCE OF SARCOPENIA 59
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 59
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 60
6.2 RESTRAINTS 61
6.2.1 LACK OF STANDARDIZED DIAGNOSIS 61
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 61
6.3 OPPORTUNITIES 62
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 62
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 62
6.4 CHALLENGES 63
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 63
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 64
7 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 65
7.1 OVERVIEW 66
7.2 VITAMIN/DIETARY SUPPLEMENTS 69
7.2.1 VITAMIN SUPPLEMENTS 70
7.2.2 PROTEIN SUPPLEMENTS 70
7.2.3 FATTY ACID SUPPLEMENTS 70
7.2.4 CREATINE 70
7.2.5 WHEY PROTEINS 70
7.2.6 L-CARNITINE 70
7.2.7 SOY 70
7.2.8 BETA-ALANINE 70
7.2.9 OSTARINE 70
7.2.10 COLLAGEN PEPTIDES 70
7.2.11 LIGANDROL 71
7.2.12 BRANCH-CHAIN AMINO ACIDS 71
7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 71
7.2.14 MEDIUM CHAIN TRIGLYCERIDES 71
7.2.15 OTHERS 71
7.3 MEDICATIONS 71
7.3.1 OFF LABEL DRUGS 72
7.3.2 EMERGING DRUGS 72
- 7.3.2.1 ACE INHIBITORS 72
- 7.3.2.2 APPETITE STIMULANTS 72
- 7.3.2.3 ORAL ANTIDIABETIC DRUGS 72
- 7.3.2.4 OTHERS 73
7.4 OTHERS 73
8 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE 74
8.1 OVERVIEW 75
8.2 PRIMARY SARCOPENIA 78
8.2.1 VITAMIN/DIETARY SUPPLEMENTS 78
8.2.2 MEDICATIONS 78
8.2.3 OTHERS 78
8.3 SECONDARY SARCOPENIA 79
8.3.1 VITAMIN/DIETARY SUPPLEMENTS 79
8.3.2 MEDICATIONS 79
8.3.3 OTHERS 79
9 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES 80
9.1 OVERVIEW 81
9.2 PRE-SARCOPENIA 84
9.3 SARCOPENIA 84
9.4 SEVERE SARCOPENIA 85
10 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 86
10.1 OVERVIEW 87
10.2 ORAL 90
10.3 INJECTABLES 90
10.4 OTHERS 91
11 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER 92
11.1 OVERVIEW 93
11.2 MALE 96
11.3 FEMALE 96
12 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER 97
12.1 OVERVIEW 98
12.2 HOSPITALS 101
12.2.1 PUBLIC 101
12.2.2 PRIVATE 101
12.3 SPECIALTY CLINICS 102
12.4 HOME HEALTHCARE 102
12.5 OTHERS 103
13 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 104
13.1 OVERVIEW 105
13.2 DIRECT TENDER 108
13.3 RETAIL SALES 108
13.3.1 HOSPITAL PHARMACIES 109
13.3.2 ONLINE PHARMACIES 109
13.3.3 OTHERS 109
13.4 OTHERS 109
14 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY REGION 110
14.1 ASIA-PACIFIC 113
14.1.1 JAPAN 120
14.1.2 CHINA 127
14.1.3 SOUTH KOREA 133
14.1.4 INDIA 139
14.1.5 AUSTRALIA 145
14.1.6 SINGAPORE 151
14.1.7 THAILAND 157
14.1.8 MALAYSIA 163
14.1.9 INDONESIA 169
14.1.10 PHILIPPINES 175
14.1.11 VIETNAM 181
14.1.12 NEW ZEALAND 187
14.1.13 TAIWAN 193
14.1.14 REST OF ASIA-PACIFIC 199
15 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 200
15.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 200
16 SWOT ANALYSIS 201
17 COMPANY PROFILE 202
17.1 ABBOTT 202
17.1.1 COMPANY SNAPSHOT 202
17.1.2 REVENUE ANALYSIS 202
17.1.3 COMPANY SHARE ANALYSIS 203
17.1.4 PRODUCT PORTFOLIO 203
17.1.5 RECENT DEVELOPMENT 203
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 204
17.2.1 COMPANY SNAPSHOT 204
17.2.2 REVENUE ANALYSIS 204
17.2.3 COMPANY SHARE ANALYSIS 205
17.2.4 PRODUCT PORTFOLIO 205
17.2.5 RECENT DEVELOPMENT 205
17.3 NOVARTIS AG 206
17.3.1 COMPANY SNAPSHOT 206
17.3.2 REVENUE ANALYSIS 206
17.3.3 COMPANY SHARE ANALYSIS 207
17.3.4 PRODUCT PORTFOLIO 207
17.3.5 PIPELINE PORTFOLIO 207
17.3.6 RECENT DEVELOPMENT 207
17.4 SANOFI 208
17.4.1 COMPANY SNAPSHOT 208
17.4.2 REVENUE ANALYSIS 208
17.4.3 COMPANY SHARE ANALYSIS 209
17.4.4 PRODUCT PORTFOLIO 209
17.4.5 RECENT DEVELOPMENT 209
17.5 HALEON GROUP OF COMPANIES 210
17.5.1 COMPANY SNAPSHOT 210
17.5.2 REVENUE ANALYSIS 210
17.5.3 COMPANY SHARE ANALYSIS 211
17.5.4 PRODUCT PORTFOLIO 211
17.5.5 RECENT DEVELOPMENT 211
17.6 ASTAREAL CO., LTD 212
17.6.1 COMPANY SNAPSHOT 212
17.6.2 PRODUCT PORTFOLIO 212
17.6.3 RECENT DEVELOPMENT 212
17.7 BASF SE 213
17.7.1 COMPANY SNAPSHOT 213
17.7.2 REVENUE ANALYSIS 213
17.7.3 PRODUCT PORTFOLIO 214
17.7.4 RECENT DEVELOPMENT 214
17.8 BIOGEN SA 215
17.8.1 COMPANY SNAPSHOT 215
17.8.2 PRODUCT PORTFOLIO 215
17.8.3 RECENT DEVELOPMENT 215
17.9 BIOTHRIVE SCIENCES 216
17.9.1 COMPANY SNAPSHOT 216
17.9.2 PRODUCT PORTFOLIO 216
17.9.3 RECENT DEVELOPMENT 216
17.10 DSM 217
17.10.1 COMPANY SNAPSHOT 217
17.10.2 REVENUE ANALYSIS 217
17.10.3 PRODUCT PORTFOLIO 218
17.10.4 RECENT DEVELOPMENT 218
17.11 FERMENTA BIOTECH LIMITED 219
17.11.1 COMPANY SNAPSHOT 219
17.11.2 REVENUE ANALYSIS 219
17.11.3 PRODUCT PORTFOLIO 220
17.11.4 RECENT DEVELOPMENT 220
17.12 HEALING PHARMA INDIA PVT. LTD 221
17.12.1 COMPANY SNAPSHOT 221
17.12.2 PRODUCT PORTFOLIO 221
17.12.3 RECENT DEVELOPMENT 221
17.13 METAGENICS 222
17.13.1 COMPANY SNAPSHOT 222
17.13.2 PRODUCT PORTFOLIO 222
17.13.3 RECENT DEVELOPMENT 222
17.14 THE VITAMIN COMPANY INDIA 223
17.14.1 COMPANY SNAPSHOT 223
17.14.2 PRODUCT PORTFOLIO 223
17.14.3 RECENT DEVELOPMENT 223
17.15 WELLONA PHARMA 224
17.15.1 COMPANY SNAPSHOT 224
17.15.2 PRODUCT PORTFOLIO 224
17.15.3 RECENT DEVELOPMENT 224
17.16 ARMGO PHARMA, INC 225
17.16.1 COMPANY SNAPSHOT 225
17.16.2 PIPELINE PORTFOLIO 225
17.16.3 RECENT DEVELOPMENT 225
17.17 BIOPHYTIS 226
17.17.1 COMPANY SNAPSHOT 226
17.17.2 PIPELINE PORTFOLIO 226
17.17.3 RECENT DEVELOPMENT 226
17.18 DYSTROGEN THERAPEUTICS CORP 227
17.18.1 COMPANY SNAPSHOT 227
17.18.2 PIPELINE PORTFOLIO 227
17.18.3 RECENT DEVELOPMENT 227
17.19 IMMUNOFORGE INC 228
17.19.1 COMPANY SNAPSHOT 228
17.19.2 PIPELINE PORTFOLIO 228
17.19.3 RECENT DEVELOPMENT 228
17.20 MYMD PHARMACEUTICALS 229
17.20.1 COMPANY SNAPSHOT 229
17.20.2 PIPELINE PORTFOLIO 229
17.20.3 RECENT DEVELOPMENT 229
17.21 NMD PHARMA A/S 230
17.21.1 COMPANY SNAPSHOT 230
17.21.2 PIPELINE PORTFOLIO 230
17.21.3 RECENT DEVELOPMENT 230
17.22 ONCOCROSS CO., LTD 231
17.22.1 COMPANY SNAPSHOT 231
17.22.2 PIPELINE PORTFOLIO 231
17.22.3 RECENT DEVELOPMENT 231
17.23 OPKO HEALTH, INC 232
17.23.1 COMPANY SNAPSHOT 232
17.23.2 REVENUE ANALYSIS 232
17.23.3 PIPELINE PORTFOLIO 233
17.23.4 RECENT DEVELOPMENT 233
17.24 REGENERON PHARMACEUTICALS INC 234
17.24.1 COMPANY SNAPSHOT 234
17.24.2 REVENUE ANALYSIS 234
17.24.3 PIPELINE PORTFOLIO 235
17.24.4 RECENT DEVELOPMENT 235
17.25 REJUVENATE BIOMED NV 236
17.25.1 COMPANY SNAPSHOT 236
17.25.2 PIPELINE PORTFOLIO 236
17.25.3 RECENT DEVELOPMENT 236
18 QUESTIONNAIRE 237
19 RELATED REPORTS 241